Lonza wins exclusive 5-year manufacturing contract from Index ventures

Lonza wins exclusive 5-year manufacturing contract from Index ventures

Related tags Investment Lonza

Lonza has been selected to develop and manufacture all biologics for the biotech companies in capital investment firm Index Ventures' portfolio.

The venture firm announced it had entered into an exclusive agreement with the Switzerland-headquartered contract manufacturing organization (CMO) Lonza this morning. The five-year deal will see Lonza fulfill all process development and GMP production of biological products in the portfolio of companies where Index is the major investor.

According to Dr. Stephan Kutzer, COO Lonza Pharma & Biotech, “this multi-product agreement demonstrates Lonza's ability to offer world-class expression platforms in combination with secure manufacturing capabilities for the complete product lifecycle.”

Kevin Johnson, Partner at Index Ventures said Lonza had been selected in part due to previous antibody products he had worked on in the last 20 years and this deal will enable Index’ asset-centric portfolio companies “to benefit as though they were much larger organisations.”

According to its website​, Index has 31 mostly start-up and small biotech Life Science companies in its portfolio. 

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers